Chubb Henry, Motonaga Kara S
Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, CA, USA.
Division of Pediatric Cardiothoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA, USA.
Heart Fail Rev. 2020 Jul;25(4):657-670. doi: 10.1007/s10741-019-09886-y.
Cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillators (ICDs) are well-established therapies for adult patients with heart failure that have been shown to improve morbidity and mortality. However, the benefits and indications for use in adults with congenital heart disease (ACHD) are less defined with no significant large prospective studies in this population. There are, however, multiple retrospective studies that demonstrate the efficacy of these devices in the ACHD population. These indicate a role for both CRT and ICDs in select patients with ACHD. The clinician and patient must balance the risks and benefits, summarized in complex evidence that reflects the heterogeneity of the ACHD patient group, and apply them in a patient-specific manner to optimize the utility of CRT and ICDs.
心脏再同步治疗(CRT)和植入式心脏复律除颤器(ICD)是用于成年心力衰竭患者的成熟疗法,已被证明可改善发病率和死亡率。然而,对于患有先天性心脏病的成人(ACHD),其使用的益处和适应症尚不明确,该人群中尚无显著的大型前瞻性研究。不过,有多项回顾性研究证明了这些设备在ACHD人群中的疗效。这些研究表明CRT和ICD在部分ACHD患者中均有作用。临床医生和患者必须权衡风险和益处,这些风险和益处在反映ACHD患者群体异质性的复杂证据中进行了总结,并以针对患者的方式应用它们,以优化CRT和ICD的效用。